Nurix Therapeutics, Inc. NRIX Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s operating lease right-of-use asset amortization?
- Nurix Therapeutics, Inc. (NRIX) reported operating lease right-of-use asset amortization of $1.58M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- Nurix Therapeutics, Inc.'s operating lease right-of-use asset amortization decreased by 11.1% year-over-year, from $1.78M to $1.58M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s operating lease right-of-use asset amortization has grown at a 32.4% compound annual growth rate (CAGR), from $3.29M to $10.12M.